drugset
drugset / Trial / NCT05008666

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

NCT05008666 ↗

Phase 2 Unknown 37 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection，and advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH). ENKTL-HLH lacks standard treatment and experiences a extremely poor prognosis. Anti-PD-1 antibody has shown good anti-tumor activity in ENKTL and play a potential role in EBV-HLH. Epigenetic drugs have been confirmed to exert synergistic anti-tumor activity with anti-PD-1 antibody. We next further explore the efficacy and safety of Sintilimab sequential combination of epigenetic drugs in ENKTL-HLH.

Timeline

Start
2021-12-01
Primary completion
2022-11-30
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Subject Tucidinostat Small molecule 30 mg Oral

Indications

No indication recorded.